{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:26:55Z","timestamp":1794886015345,"version":"4.9.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,23]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Ibrutinib induced a high rate of sustained responses for patients with cGVHD and inadequate response to corticosteroid-containing therapy. This trial supported the approval of ibrutinib for treatment of adult patients with cGVHD after failure of \u22651 lines of systemic therapy.<\/jats:p>","DOI":"10.1182\/blood-2017-07-793786","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T21:00:16Z","timestamp":1505768416000},"page":"2243-2250","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":483,"title":["Ibrutinib for chronic graft-versus-host disease after failure of prior therapy"],"prefix":"10.1182","volume":"130","author":[{"given":"David","family":"Miklos","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey S.","family":"Cutler","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan","family":"Jagasia","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskra","family":"Pusic","sequence":"additional","affiliation":[{"name":"Division of Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"name":"University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chang","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu","family":"Lal","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Dubovsky","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danelle F.","family":"James","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Styles","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111903522178700_B1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.beha.2010.09.016","article-title":"Have we made progress in the management of chronic graft-vs-host disease?","volume":"23","author":"Lee","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"24","key":"2019111903522178700_B2","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1182\/blood-2010-12-323824","article-title":"Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis","volume":"117","author":"Arora","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111903522178700_B3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation","volume":"341","author":"Soci\u00e9","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111903522178700_B4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2019111903522178700_B5","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","article-title":"Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study","volume":"108","author":"Fraser","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111903522178700_B6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2040620713489842","article-title":"Treatment and management of graft-versus-host disease: improving response and survival","volume":"4","author":"Garnett","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"2019111903522178700_B7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111903522178700_B8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2011.05.016","article-title":"Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children\u2019s Oncology Group study","volume":"18","author":"Gilman","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111903522178700_B9","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V96.12.3995","article-title":"Thalidomide for treatment of patients with chronic graft-versus-host disease","volume":"96","author":"Koc","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2019111903522178700_B10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V100.1.48","article-title":"Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone","volume":"100","author":"Koc","year":"2002","journal-title":"Blood"},{"issue":"21","key":"2019111903522178700_B11","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111903522178700_B12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood.V72.2.546.546","article-title":"Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation","volume":"72","author":"Sullivan","year":"1988","journal-title":"Blood"},{"issue":"12","key":"2019111903522178700_B13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbmt.2008.09.017","article-title":"Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease","volume":"14","author":"Flowers","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111903522178700_B14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MOH.0b013e32834ba87d","article-title":"Treatment of chronic graft-versus-host disease in 2011","volume":"18","author":"Inamoto","year":"2011","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"2019111903522178700_B15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2019111903522178700_B16","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2013-10-533562","article-title":"Increased BCR responsiveness in B cells from patients with chronic GVHD","volume":"123","author":"Allen","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2019111903522178700_B17","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-03-562231","article-title":"Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans","volume":"123","author":"Flynn","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111903522178700_B18","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2004-09-3660","article-title":"Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission","volume":"105","author":"Miklos","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111903522178700_B19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbmt.2014.10.029","article-title":"B cells in chronic graft-versus-host disease","volume":"21","author":"Sarantopoulos","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111903522178700_B20","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2005-04-1614","article-title":"Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation","volume":"106","author":"Pavletic","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111903522178700_B21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2016.148510","article-title":"Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Baron","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2019111903522178700_B22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12185-015-1782-4","article-title":"Therapeutic benefits targeting B-cells in chronic graft-versus-host disease","volume":"101","author":"Nakasone","year":"2015","journal-title":"Int J Hematol"},{"issue":"9","key":"2019111903522178700_B23","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.4049\/jimmunol.179.9.6369-a","article-title":"Bruton\u2019s tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family [published correction appears in","volume":"179","author":"Shinners","year":"2007","journal-title":"J Immunol"},{"issue":"15","key":"2019111903522178700_B24","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111903522178700_B25","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"issue":"25","key":"2019111903522178700_B26","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2016-06-715284","article-title":"Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT","volume":"128","author":"Ryan","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111903522178700_B27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report","volume":"12","author":"Pavletic","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111903522178700_B28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111903522178700_B29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111903522178700_B30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5045\/kjh.2011.46.3.153","article-title":"Treatment of chronic graft-versus-host disease: Past, present and future","volume":"46","author":"Martin","year":"2011","journal-title":"Korean J Hematol"},{"issue":"7","key":"2019111903522178700_B31","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3026(15)00095-2","article-title":"Consensus recommendations for improvement of unmet clinical needs--the example of chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"2","author":"Olivieri","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"2019111903522178700_B32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2017-03-775767","article-title":"An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease","volume":"130","author":"Martin","year":"2017","journal-title":"Blood"},{"issue":"30","key":"2019111903522178700_B33","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2012.42.3038","article-title":"Delivering care to long-term adult survivors of hematopoietic cell transplantation","volume":"30","author":"Syrjala","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111903522178700_B34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1432-2277.2006.00278.x","article-title":"The down-regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)-treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalization","volume":"19","author":"Bladon","year":"2006","journal-title":"Transpl Int"},{"issue":"6","key":"2019111903522178700_B35","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2007-08-106286","article-title":"Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children\u2019s Oncology Group","volume":"111","author":"Fujii","year":"2008","journal-title":"Blood"},{"key":"2019111903522178700_B36","first-page":"23","article-title":"The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics","volume-title":"Front Pharmacol","author":"Castor","year":"2012"},{"issue":"24","key":"2019111903522178700_B37","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2015-09-668251","article-title":"Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells","volume":"127","author":"Kariminia","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111903522178700_B38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-009-0272-y","article-title":"Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease","volume":"89","author":"Miklos","year":"2009","journal-title":"Int J Hematol"},{"issue":"1","key":"2019111903522178700_B39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1189\/jlb.0306231","article-title":"Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects","volume":"81","author":"Ueha","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2019111903522178700_B40","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1167\/iovs.15-18615","article-title":"Biomarkers in ocular chronic graft versus host disease: tear cytokine- and chemokine-based predictive model","volume":"57","author":"Cocho","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2019111903522178700_B41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/21\/2243\/1403803\/blood793786.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/21\/2243\/1403803\/blood793786.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:52:38Z","timestamp":1574135558000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/21\/2243\/36673\/Ibrutinib-for-chronic-graftversushost-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,23]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017,11,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-793786","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,23]]}}}